Zhuhai Rundu Pharmaceutical Co Ltd Class A
Zhuhai Rundu Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of chemical pharmaceutical preparations, APIs, and pharmaceutical intermediates in China and internationally. It offers FDF for cardiovascular; and pellets for excipient, antiulcerative, diabetes drug, anti-inflammatory, and anti-anginals. The company is also involved in the process development, qu… Read more
Market Cap & Net Worth: Zhuhai Rundu Pharmaceutical Co Ltd Class A (002923)
Zhuhai Rundu Pharmaceutical Co Ltd Class A (SHE:002923) has a market capitalization of $724.35 Million (CN¥5.31 Billion) as of March 18, 2026. Listed on the SHE stock exchange, this China-based company holds position #13363 globally and #3442 in its home market, demonstrating a -0.81% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Zhuhai Rundu Pharmaceutical Co Ltd Class A's stock price CN¥15.87 by its total outstanding shares 334893286 (334.89 Million).
Zhuhai Rundu Pharmaceutical Co Ltd Class A Market Cap History: 2018 to 2026
Zhuhai Rundu Pharmaceutical Co Ltd Class A's market capitalization history from 2018 to 2026. Data shows growth from $344.94 Million to $724.35 Million (11.65% CAGR).
Zhuhai Rundu Pharmaceutical Co Ltd Class A Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Zhuhai Rundu Pharmaceutical Co Ltd Class A's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.37x
Zhuhai Rundu Pharmaceutical Co Ltd Class A's market cap is 0.37 times its annual revenue
1.01x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
10.92x
Zhuhai Rundu Pharmaceutical Co Ltd Class A's market cap is 10.92 times its annual earnings
10.29x
Higher than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2018 | $344.94 Million | $1.04 Billion | $106.84 Million | 0.33x | 3.23x |
| 2019 | $391.03 Million | $1.36 Billion | $118.90 Million | 0.29x | 3.29x |
| 2020 | $370.52 Million | $1.25 Billion | $135.86 Million | 0.30x | 2.73x |
| 2021 | $574.12 Million | $1.19 Billion | $139.77 Million | 0.48x | 4.11x |
| 2022 | $545.89 Million | $1.37 Billion | $155.48 Million | 0.40x | 3.51x |
| 2023 | $552.68 Million | $1.29 Billion | $66.90 Million | 0.43x | 8.26x |
| 2024 | $435.43 Million | $1.18 Billion | $39.88 Million | 0.37x | 10.92x |
Competitor Companies of 002923 by Market Capitalization
Companies near Zhuhai Rundu Pharmaceutical Co Ltd Class A in the global market cap rankings as of March 18, 2026.
Key companies related to Zhuhai Rundu Pharmaceutical Co Ltd Class A by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #423 globally with a market cap of $51.97 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #455 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #719 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #423 | Zoetis Inc | NYSE:ZTS | $51.97 Billion | $118.15 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.46 |
| #455 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #719 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
Zhuhai Rundu Pharmaceutical Co Ltd Class A Historical Marketcap From 2018 to 2026
Between 2018 and today, Zhuhai Rundu Pharmaceutical Co Ltd Class A's market cap moved from $344.94 Million to $ 724.35 Million, with a yearly change of 11.65%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥724.35 Million | +30.62% |
| 2025 | CN¥554.56 Million | +27.36% |
| 2024 | CN¥435.43 Million | -21.21% |
| 2023 | CN¥552.68 Million | +1.24% |
| 2022 | CN¥545.89 Million | -4.92% |
| 2021 | CN¥574.12 Million | +54.95% |
| 2020 | CN¥370.52 Million | -5.25% |
| 2019 | CN¥391.03 Million | +13.36% |
| 2018 | CN¥344.94 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 17th, 2026 the market cap of Zhuhai Rundu Pharmaceutical Co Ltd Class A was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $724.35 Million USD |
| MoneyControl | $724.35 Million USD |
| MarketWatch | $724.35 Million USD |
| marketcap.company | $724.35 Million USD |
| Reuters | $724.35 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.